Responsibilities beyond financial results
Directors of hospitals, diagnostic groups and pharmaceutical companies in Bangladesh carry responsibilities that reach beyond profit. A clinical incident, a failed product inspection or a lapsed licence can damage an organisation faster than a weak quarter. Boards are therefore asking management for regular reporting on licensing status, regulatory inspections, patient complaints and product quality, alongside the financial pack. Clinical governance is primarily the responsibility of medical leadership, but the board needs assurance that the right committees exist, meet regularly and escalate issues. They also want to know how these risks would affect provisions, disclosures and reputation if something went wrong.
Capital allocation for equipment and expansion
New hospital wings, imaging equipment, laboratories and manufacturing lines require large investments, often with imported components priced in foreign currency. Boards want investment cases that test utilisation assumptions, pricing, staffing and financing costs, and they want post-investment reviews that compare results with the original case. Financing structure matters as much as the investment itself: borrowing in foreign currency for imported equipment, or funding long-term assets with short-term facilities, can strain liquidity if patient volumes build more slowly than planned. Where a decision is significant or contested, an independent appraisal from RRH's Corporate Finance team gives directors a basis for challenge.
Integrity of revenue, procurement and inventory
Healthcare boards are paying closer attention to where money can leak. In providers, that means unbilled services, unauthorised discounts and payments to referring practitioners or agents, which need clear policy and transparent accounting. In pharmaceuticals, it means promotional spending, distributor arrangements and write-offs of expired stock. Across both, procurement of medicines, consumables and equipment is an area where conflicts of interest can arise. Boards are asking whether management uses data analysis to spot unusual patterns, such as discounts concentrated on particular staff or referral sources.
When concerns or allegations surface, our Forensic Services team carries out independent investigations and reports findings directly to the board or audit committee, so that decisions rest on established facts.
Regulatory readiness and independent assurance
For pharmaceutical boards, the questions include readiness for DGDA and export market inspections and the business effect of Bangladesh's graduation from least developed country status. For listed healthcare companies, BSEC governance and disclosure requirements add further oversight duties. Directors are also asking about succession for key clinical and technical staff, whose departure can weaken quality systems and regulatory standing.
Many boards are strengthening the assurance that supports these duties. RRH's Risk Consulting team provides risk-based internal audit and compliance reviews that report to the audit committee, giving directors an independent view of whether controls and regulatory processes are working as management describes.
Related RRH services: Corporate Finance, Forensic Services and Risk Consulting.